Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trial.
Manon-Jensen T, Tangada S, Bager C, Chowdary P, Klamroth R, von Drygalski A, Windyga J, Escobar M, Frederiksen P, Engl W, Ewenstein B, Karsdal M. Manon-Jensen T, et al. Among authors: tangada s. J Thromb Haemost. 2024 Jan;22(1):90-100. doi: 10.1016/j.jtha.2023.08.035. Epub 2023 Sep 16. J Thromb Haemost. 2024. PMID: 37717853 Free article. Clinical Trial.
Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
Gruppo R, López-Fernández MF, Wynn TT, Engl W, Sharkhawy M, Tangada S. Gruppo R, et al. Among authors: tangada s. Haemophilia. 2019 Sep;25(5):773-781. doi: 10.1111/hae.13807. Epub 2019 Jul 28. Haemophilia. 2019. PMID: 31353761 Free PMC article. Clinical Trial.
Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A.
Motwani J, Guillet B, Blatny J, Schilling FH, Wibaut B, Goldstine J, Nagy A, Doralt J, Engl W, Tangada S, Spotts G. Motwani J, et al. Among authors: tangada s. Haemophilia. 2020 May;26(3):478-486. doi: 10.1111/hae.13997. Epub 2020 Apr 27. Haemophilia. 2020. PMID: 32338433 Free PMC article.
Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Chowdary P, Mullins ES, Konkle BA, McGuinn C, Park YS, Stasyshyn O, Zulfikar B, Engl W, Tangada S. Chowdary P, et al. Among authors: tangada s. Haemophilia. 2020 Jul;26(4):e168-e178. doi: 10.1111/hae.14052. Epub 2020 Jun 28. Haemophilia. 2020. PMID: 32597029 Clinical Trial.
Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.
Windyga J, Timofeeva M, Stasyshyn O, Mamonov V, Lamas Castellanos JL, Lissitchkov T, Chojnowski K, Chapman M, Pavlova BG, Tangada S. Windyga J, et al. Among authors: tangada s. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620946839. doi: 10.1177/1076029620946839. Clin Appl Thromb Hemost. 2020. PMID: 32816519 Free PMC article. Clinical Trial.
Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery.
Pabinger I, Mamonov V, Windyga J, Engl W, Doralt J, Tangada S, Spotts G, Ewenstein B. Pabinger I, et al. Among authors: tangada s. Haemophilia. 2021 May;27(3):e331-e339. doi: 10.1111/hae.14219. Epub 2021 Mar 27. Haemophilia. 2021. PMID: 33772963 Free PMC article. Clinical Trial.
23 results